Blog
RSS FeedPosted by Michael Wonder on 08 Apr 2026
Cancer clinicians call for three actions Canada's health systems should take to improve cancer care
7 April 2026 - April Cancer Awareness Month a good time for concrete action ...
Posted by Michael Wonder on 18 Mar 2026
When generic versions of weight loss drugs arrive, public plans should cover them, experts say
17 March 2026 - When Bonnie Evoy entered her mid 60s, she unexpectedly and rapidly gained weight. She tried for ...
Posted by Michael Wonder on 03 Mar 2026
Alnylam receives positive recommendation from Canada's Drug Agency for the public reimbursement of Amvuttra (vutrisiran injection), the first and only RNAi therapeutic for the treatment of cardiomyopathy in adult patients with ATTR amyloidosis
2 March 2026 - Alnylam Canada is pleased to announce it has received a positive recommendation from Canada's Drug Agency for ...
Posted by Michael Wonder on 28 Feb 2026
Ontario becomes the first province to publicly reimburse the first targeted oral therapy for adults with grade 2 IDH-mutant glioma
27 February 2026 - Servier Canada announces Ontario coverage of Voranigo under the FAST program. ...
Posted by Michael Wonder on 21 Feb 2026
Canada's public drug plans shouldn't cover new Alzheimer's drug, agency says
19 February 2026 - Lecanemab, also known as Leqembi, is approved to treat mild cognitive impairment, early Alzheimer's. ...
Posted by Michael Wonder on 11 Feb 2026
Canadians wait, on average, more than 65 weeks longer for access to new medicines than Europeans and 90 weeks more than Americans
10 February 2025 - Canadian patients are waiting, on average, more than 65 weeks longer than Europeans and over 90 ...
Posted by Michael Wonder on 07 Feb 2026
Kisqali receives positive draft recommendation from Canada's Drug Agency for all eligible early breast cancer patients at high risk of recurrence
6 February 2026 - The draft recommendation for Kisqali (ribociclib tablets) from Canada's Drug Agency (CDA-AMC) supports public reimbursement for hormone ...
Posted by Michael Wonder on 04 Feb 2026
Rezurock now reimbursed in Ontario and British Columbia for people living with chronic graft versus host disease
3 February 2026 - British Columbia and Ontario recently added Rezurock (belumosudil) to their provincial formularies for adult and pediatric patients ...
Posted by Michael Wonder on 04 Feb 2026
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer
3 February 2026 - GSK announced today that Quebec has become the first Canadian province to publicly reimburse Jemperli (dostarlimab for ...
Posted by Michael Wonder on 30 Jan 2026
Canadians wait too long for access to innovative drugs, cautions the MEI
29 January 2026 - Pharmaceutical innovation is responsible for up to 66% of the increase in the age of death ...
Posted by Michael Wonder on 30 Jan 2026
Government of Canada announces the new Chairperson of the Patented Medicine Prices Review Board
29 January 2026 - Today, the Honourable Marjorie Michel, Minister of Health, announced the designation of a new Chairperson for ...
Posted by Michael Wonder on 26 Jan 2026
Patient organisations welcome approval of six life-extending cancer treatments through Ontario's FAST Program, urge national expansion
23 January 2026 - Leading patient organisations are welcoming Ontario's announcement that six cancer drugs are now being fast-tracked for ...
Posted by Michael Wonder on 26 Jan 2026
AstraZeneca's Tagrisso and Calquence among first oncology treatments granted accelerated access through Ontario's FAST Program
23 January 2026 - AstraZeneca Canada is pleased to announce that Tagrisso (osimertinib) and Calquence (acalabrutinib tablets) are now publicly funded ...
Posted by Michael Wonder on 15 Jan 2026
Ontario pioneers access to treatment for severe alopecia areata with Lilly's Olumiant
14 January 2026 - Eli Lilly Canada announced today that Ontario leads the way as the first province to add Olumiant ...
Posted by Michael Wonder on 20 Dec 2025
Eli Lilly cuts price of diabetes, weight loss drugs in Canada
17 December 2025 - Eli Lilly is slashing the prices of its popular diabetes and weight loss drugs Mounjaro and ...